Interleukin-1

Mené sur 52 patients atteints d'un cancer métastatique réfractaire (18 types différents), cet essai de phase I en escalade de dose évalue la toxicité et l'activité antitumorale d'un anticorps monoclonal (MABp1) ciblant l'interleukine

Résumé en anglais

Inflammation contributes to the severity of most diseases, and cytokine-specific blocking treatments are well established for autoinflammatory and autoimmune diseases. However, cytokine-mediated inflammation also has a role in the pathogenesis of cancer; for example, in the immunosuppression of the disease. Cytokine-mediated systemic inflammation is also a debilitating aspect of cancer. Many tumours produce inflammatory cytokines, which promote angiogenesis and tumour growth. Therefore, blocking ...